AdaptHealth Corp. (NASDAQ:AHCO) Given Consensus Rating of "Hold" by Brokerages

Key Points

• AdaptHealth Corp. (NASDAQ: AHCO) has received a consensus rating of "Hold" from seven analysts, with two recommending a sell and five a buy, and the average target price is set at $13.40.
• Recent analyst updates included Zacks lowering the rating to "strong sell," while Wall Street Zen upgraded it to "strong buy," showing conflicting perspectives on the stock's future.
• Insiders hold 1.55% of the company's stock, and director David Solomon Williams III sold 8,200 shares, indicating a decrease in his position by 14.08%.

AdaptHealth Corp. (NASDAQ:AHCO - Get Free Report) has been assigned an average rating of "Hold" from the seven analysts that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $13.40.

AHCO has been the topic of several recent analyst reports. Zacks Research lowered AdaptHealth from a "hold" rating to a "strong sell" rating in a research note on Friday, September 19th. Weiss Ratings reiterated a "sell (d+)" rating on shares of AdaptHealth in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded AdaptHealth from a "buy" rating to a "strong-buy" rating in a research note on Sunday.

AdaptHealth Price Performance

Shares of NASDAQ AHCO opened at $9.44 on Thursday. The stock has a market capitalization of $1.28 billion, a PE ratio of 17.48, a P/E/G ratio of 1.19 and a beta of 1.61. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.06 and a quick ratio of 0.82. The business has a fifty day moving average price of $9.18 and a two-hundred day moving average price of $9.00. AdaptHealth has a fifty-two week low of $7.11 and a fifty-two week high of $11.63.

Insider Activity

In other news, Director David Solomon Williams III sold 8,200 shares of AdaptHealth stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $9.73, for a total value of $79,786.00. Following the transaction, the director owned 50,045 shares in the company, valued at approximately $486,937.85. This trade represents a 14.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.55% of the company's stock.

Hedge Funds Weigh In On AdaptHealth

Several hedge funds and other institutional investors have recently modified their holdings of the business. Reinhart Partners LLC. increased its stake in shares of AdaptHealth by 1.1% in the 2nd quarter. Reinhart Partners LLC. now owns 7,312,626 shares of the company's stock valued at $68,958,000 after purchasing an additional 76,364 shares during the last quarter. Palisade Capital Management LP grew its position in AdaptHealth by 12.3% during the 1st quarter. Palisade Capital Management LP now owns 2,711,142 shares of the company's stock worth $29,389,000 after acquiring an additional 297,268 shares during the last quarter. Invesco Ltd. grew its position in AdaptHealth by 50.0% during the 2nd quarter. Invesco Ltd. now owns 1,906,074 shares of the company's stock worth $17,974,000 after acquiring an additional 634,973 shares during the last quarter. Iron Triangle Partners LP bought a new stake in AdaptHealth during the 1st quarter worth $17,496,000. Finally, Charles Schwab Investment Management Inc. grew its position in AdaptHealth by 14.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,301,652 shares of the company's stock worth $14,110,000 after acquiring an additional 163,272 shares during the last quarter. Institutional investors own 82.67% of the company's stock.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.